DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,603,319 | +25.0% | 95,136 | +20.9% | 1.01% | +31.1% |
| Q2 2023 | $18,885,840 | -5.5% | 78,691 | -0.8% | 0.77% | -9.1% |
| Q1 2023 | $19,994,200 | -4.7% | 79,330 | +0.4% | 0.85% | -10.3% |
| Q4 2022 | $20,980,674 | +0.1% | 79,047 | -2.6% | 0.94% | -9.1% |
| Q3 2022 | $20,966,000 | +3.6% | 81,173 | +1.7% | 1.04% | +10.3% |
| Q2 2022 | $20,237,000 | -14.5% | 79,823 | -1.1% | 0.94% | -0.6% |
| Q1 2022 | $23,664,000 | -10.2% | 80,675 | +0.7% | 0.95% | -5.0% |
| Q4 2021 | $26,349,000 | +4.6% | 80,087 | -3.2% | 1.00% | -1.8% |
| Q3 2021 | $25,190,000 | +12.5% | 82,742 | -0.8% | 1.01% | -3.2% |
| Q2 2021 | $22,389,000 | +16.4% | 83,430 | -2.4% | 1.05% | +8.5% |
| Q1 2021 | $19,233,000 | +1.9% | 85,447 | +0.6% | 0.96% | -10.6% |
| Q4 2020 | $18,872,000 | +2.7% | 84,957 | -0.5% | 1.08% | -7.9% |
| Q3 2020 | $18,377,000 | +19.4% | 85,343 | -1.9% | 1.17% | +10.2% |
| Q2 2020 | $15,389,000 | +28.4% | 87,028 | +0.5% | 1.06% | +9.2% |
| Q1 2020 | $11,986,000 | -10.5% | 86,600 | -0.7% | 0.97% | +10.8% |
| Q4 2019 | $13,387,000 | +6.1% | 87,224 | -0.1% | 0.88% | -3.4% |
| Q3 2019 | $12,614,000 | +1.4% | 87,337 | +0.4% | 0.91% | -22.9% |
| Q2 2019 | $12,435,000 | -5.6% | 87,009 | -12.8% | 1.18% | -1.3% |
| Q1 2019 | $13,172,000 | +25.9% | 99,779 | -1.7% | 1.20% | +10.9% |
| Q4 2018 | $10,462,000 | -2.4% | 101,454 | +2.9% | 1.08% | +8.8% |
| Q3 2018 | $10,715,000 | +11.7% | 98,605 | +1.4% | 0.99% | +4.3% |
| Q2 2018 | $9,595,000 | +2.3% | 97,233 | +1.5% | 0.95% | -3.7% |
| Q1 2018 | $9,376,000 | +6.8% | 95,761 | +1.2% | 0.99% | -11.9% |
| Q4 2017 | $8,783,000 | +3.7% | 94,624 | -4.1% | 1.12% | +10.8% |
| Q3 2017 | $8,468,000 | -1.2% | 98,709 | -2.8% | 1.01% | -14.2% |
| Q2 2017 | $8,573,000 | -4.1% | 101,588 | -2.8% | 1.18% | +8.9% |
| Q1 2017 | $8,938,000 | +9.3% | 104,502 | -0.5% | 1.08% | +4.8% |
| Q4 2016 | $8,176,000 | -3.1% | 105,035 | -2.4% | 1.03% | -6.3% |
| Q3 2016 | $8,438,000 | -25.3% | 107,638 | -3.7% | 1.10% | -23.9% |
| Q2 2016 | $11,293,000 | +6.9% | 111,812 | +0.4% | 1.45% | +3.9% |
| Q1 2016 | $10,568,000 | +2.4% | 111,407 | +0.3% | 1.39% | +1.2% |
| Q4 2015 | $10,320,000 | +8.3% | 111,110 | -0.6% | 1.38% | +1.2% |
| Q3 2015 | $9,526,000 | -0.8% | 111,793 | -0.4% | 1.36% | +5.0% |
| Q2 2015 | $9,602,000 | +1.1% | 112,187 | +0.3% | 1.30% | +0.7% |
| Q1 2015 | $9,496,000 | -0.9% | 111,852 | +0.0% | 1.29% | -2.1% |
| Q4 2014 | $9,585,000 | +13.5% | 111,827 | +0.6% | 1.31% | +6.4% |
| Q3 2014 | $8,448,000 | -7.3% | 111,176 | -4.0% | 1.24% | -5.7% |
| Q2 2014 | $9,116,000 | +6.4% | 115,788 | +1.4% | 1.31% | +0.5% |
| Q1 2014 | $8,568,000 | -2.4% | 114,242 | +0.5% | 1.30% | -3.0% |
| Q4 2013 | $8,777,000 | +10.4% | 113,684 | -0.9% | 1.34% | +2.5% |
| Q3 2013 | $7,950,000 | +5.4% | 114,683 | -3.7% | 1.31% | +3.8% |
| Q2 2013 | $7,541,000 | – | 119,133 | – | 1.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |